EMPOWER-Lung 1: Baseline Characteristics and Modern Treatment Considerations in NSCLC
Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
Video content above is prompted by the following:
- How does histology, staging and ECOG performance status play into treatment considerations at your practice today, and how do these factors compare to the baseline characteristics of this study?
- What other biomarkers, if any, are important in determining the efficacy of PD-1 inhibitors like cemiplimab before initiating therapy, both in NSCLC and for other indications?
- Overall, how does this patient population compare with those treated in 2025 with immune checkpoint inhibitors or other first-line treatment options for advanced NSCLC?
Related Content
Lurbinectedin and Atezolizumab Combo Improves Survival in Extensive-Stage Small-Cell Lung Cancer
June 20th 2025Article
When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies to nearly two-thirds of SCLC cases at the time of diagnosis.
Read More
